A federal consultative group voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is non-binding. The FDA has given no public comment on whether it will move in step with the panel. The move came after weeks of public comment sessions. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could change how the agency handles a part of the wellness market that is scaling quickly. Regulators are watching to see if the FDA follows through on the vote. A spokesperson offered no fixed date for a next move. Backers argue the change would expand access to substances some say help. Critics warn that looser rules could allow poor oversight across a barely regulated market. The vote only clears a path to a change, and the final say rests with the FDA.